Articles from Actio Biosciences

Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that David Goldstein, Ph.D., co-founder and CEO, will present a company overview as part of the rare disease panel at the Evercore Emerging Private Biotech Conference on Monday, July 14, 2025, at 9:00 a.m. ET in Newport, Rhode Island.

Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced the closing of a $66 million Series B financing. New investor Regeneron Ventures and current investor Deerfield Management co-led the financing, with participation from existing investors Canaan, Droia Ventures and Euclidean Capital.

Actio Biosciences, a clinical-stage biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that management will participate in one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on Wednesday, April 16th in Boston.

Actio Biosciences, a clinical-stage biotechnology company leveraging its one to many paradigm to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that the first participant has been dosed in the Phase 1 healthy volunteer clinical trial of its lead program, ABS-0871, a TRPV4 inhibitor, for the treatment of TRPV4-positive Charcot Marie Tooth Disease subtype 2C (CMT2C), a severe peripheral nerve disorder.

Actio Biosciences, a clinical-stage biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that management will participate in two upcoming investor conferences in March 2025. Details are as follows:

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced the appointment of Cayce Denton as chief financial officer. Ms. Denton brings over two decades of experience in finance, strategy, and business development within the biotech and pharmaceutical industries, most recently serving as general partner at Dandelion Capital Management.

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that David Goldstein, Ph.D., co-founder and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 5:30 p.m. PT in San Francisco.

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that management will participate in two upcoming investor conferences in November and December 2024. Details are as follows:

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that management will participate in two upcoming investor conferences in October 2024. Details are as follows:

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced the appointment of Dimitrios Arkilo, M.D., as chief medical officer (CMO). Dr. Arkilo, a trained pediatric neurologist with significant experience in childhood epilepsy, succeeds former CMO, Sam Collins, MBBS, Ph.D., who will remain a consultant with the company.

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced the U.S. Food and Drug Administration (FDA) has granted both orphan drug designation (ODD) and rare pediatric disease designation (RPDD) for ABS-0871, a TRPV4 inhibitor, for the treatment of TRPV4+ Charcot-Marie-Tooth disease subtype 2C (CMT2C).

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that Emil Kakkis, M.D., Ph.D., CEO, president and director of Ultragenyx, has joined the company’s board of directors. Dr. Kakkis, a visionary in rare disease drug development, founded Ultragenyx in 2010 to create a company that is uniquely built around a deep and meaningful engagement with patients and their caregivers to fully understand their needs.

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that Ben Cravatt, Ph.D., has joined the company’s board of directors. Dr. Cravatt is professor and Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute. His research group is interested in developing chemical proteomic technologies that enable protein and drug discovery on a global scale and applying these methods to characterize biochemical pathways that play important roles in human physiology and disease.

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that Samuel Collins, Ph.D., has joined the company as chief medical officer to oversee all aspects of clinical development, as well as medical and regulatory affairs, for the company’s pipeline of precision medicines.

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced the completion of a $55 million Series A financing. The financing was led by Canaan and DROIA Ventures, with participation from existing investors Deerfield Management and EcoR1, as well as new investor Euclidean Capital.